Form 4: Bristol-Myers Squibb Executive Cari Gallman Reports Changes in Beneficial Ownership
SEC Form 4 Filing
EVP Cari Gallman reports transactions involving Bristol-Myers Squibb common stock and market share units, including vesting, adjustments, and tax withholdings, as per Form 4 filing.
Summary
- Cari Gallman, EVP of Corporate Affairs at Bristol-Myers Squibb, filed a Form 4 detailing changes in beneficial ownership of company stock and derivative securities.
- The transactions occurred on March 10, 2024, and involve the vesting of market share units and performance shares.
- Some market share units were adjusted or cancelled due to performance factors not meeting minimum payout thresholds.
- Shares were also withheld for payment of taxes upon the vesting of awards.
- Gallman now directly owns 1,432 shares of common stock following the reported transactions.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the document primarily reports routine executive stock transactions. The cancellation of some market share units due to not meeting performance targets is a slightly negative signal, but overall the document doesn't convey strong positive or negative sentiment.
Negatives
- Cancellation of market share units due to not achieving the minimum payout factor indicates underperformance relative to targets.
Risks
- Future vesting of market share units and performance shares is contingent on achieving certain performance metrics, which may not always be met.
Future Outlook
Future vesting of market share units is dependent on the company's performance and achieving the minimum payout factors.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's confidence in the company's future prospects.
Comparison to Industry Standards
- Stock-based compensation is a common practice in the pharmaceutical industry to align executive incentives with shareholder value.
- Companies like Pfizer, Merck, and Johnson & Johnson also utilize market share units and performance shares as part of their executive compensation packages.
- The specific terms and conditions of these awards, such as vesting schedules and performance metrics, can vary significantly between companies.
Stakeholder Impact
- The vesting of executive stock options can have a dilutive effect on existing shareholders.
- Executive compensation practices are of interest to shareholders and can influence their perception of management's alignment with their interests.
Key Dates
| Date | Description |
|---|---|
| 03/10/2020 | Grant date of market share units, one-quarter of which vested on 03/10/2024. |
| 03/10/2021 | Grant date of market share units, one-quarter of which vested on 03/10/2024. |
| 03/10/2022 | Grant date of market share units, one-quarter of which were cancelled on 03/10/2024 due to not achieving the 80% minimum payout factor. |
| 03/10/2023 | Grant date of market share units, one-quarter of which were cancelled on 03/10/2024 due to not achieving the 80% minimum payout factor. |
| 03/10/2024 | Date of transactions reported in the Form 4, including vesting of market share units and performance shares. |
| 03/12/2024 | Date of Form 4 filing. |
| First quarter 2027 | Distribution of performance shares earned under the long-term performance award. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.